Jana de Boniface, MD, PhD, on Breast Cancer With Sentinel Lymph Node Macrometastases: Can Axillary Dissection Be Omitted?
ASCO 2026
Jana de Boniface, MD, PhD, of Capio Saint Göran's Hospital and Karolinska Institutet, reviews overall survival and patient-reported arm morbidity findings from the SENOMAC trial, which sought to determine if patients with breast cancer and sentinel lymph node macrometastases could omit complete axillary dissection (Abstract LBA503).
The ASCO Post Staff
Ronald C. Chen, MD, MPH, FASCO, of the University of Kansas Medical Center, presents health-related quality of life (HRQoL) data from the AMBASSADOR trial, which showed that in patients with high-risk muscle-invasive urothelial carcinoma after radical surgery, adjuvant pembrolizumab for 1 year approximately doubled disease-free survival, causes fatigue and dyspnea which modestly impacted physical function and ability to perform certain roles (such as work and hobbies), without impact on overall quality of life (Abstract 4513).
The ASCO Post Staff
Krishnansu S. Tewari, MD, of the University of California, Irvine, provides commentary on research presented in the oral abstract and rapid oral abstract sessions for gynecologic cancer, focusing on this year’s major trial data in endometrial, cervical, and ovarian cancers.
The ASCO Post Staff
Colton Jones, MD, of The University of Texas at San Antonio, talks about the results of a global, multicenter analysis that sought to determine the safety and efficacy of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) for the primary prevention of hepatocellular carcinoma (HCC) in a pan-etiology high-risk cohort (Abstract 10522).
The ASCO Post Staff
Nicholas C. Turner, MD, PhD, of the Royal Marsden Hospital, Institute of Cancer Research, discusses results from the primary analysis of the persevERA BC trial, which investigated giredestrant plus palbociclib vs letrozole plus palbociclib as first-line therapy in patients with estrogen receptor (ER)-positive, HER2-negative locally advanced or metastatic breast cancer (Abstract LBA1006).
Paolo Tarantino, MD, PhD, of Dana-Farber Cancer Institute, reviews the results of a large clinicogenomic database study that looked at overall survival by genomic profile among patients with HER2-positive metastatic breast cancer. Patients with mutations in key DNA repair genes experienced a numerically worse prognosis, representing an unmet need for drug development, say researchers (Abstract 1045).
